Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.4K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

3.1K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.1K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

2.3K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.3K
Chemical Synapses01:26

Chemical Synapses

12.4K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
12.4K
Chemical Synapses01:26

Chemical Synapses

8.1K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
8.1K
Muscle Contraction01:10

Muscle Contraction

9.2K
In skeletal muscles, acetylcholine is released by nerve terminals at the motor endplate—the point of synaptic communication between motor neurons and muscle fibers. The binding of acetylcholine to its receptors on the sarcolemma allows entry of sodium ions into the cell and triggers an action potential in the muscle cell. Thus, electrical signals from the brain are transmitted to the muscle. Subsequently, the enzyme acetylcholinesterase breaks down acetylcholine to prevent excessive...
9.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management.

European journal of neurology·2018
Same author

Survey of diagnostic and treatment practices for multiple sclerosis in Europe.

European journal of neurology·2017
Same author

[Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].

Der Nervenarzt·2016
Same author

[Current aspects of therapy conversion for multiple sclerosis].

Der Nervenarzt·2015
Same author

[Pegylated interferon beta 1a. A new therapy option for treatment of relapsing-remitting multiple sclerosis].

Der Nervenarzt·2015
Same author

[Prognostic and predictively relevant factors for multiple sclerosis].

Der Nervenarzt·2014

Related Experiment Video

Updated: Mar 23, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.9K

[Myasthenia gravis].

J Schodrowski1, M Seipelt1, I Adibi-Sedeh1

  • 1Klinik für Neurologie, Bereich Neuroimmunologie, Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg, Baldingerstr. 1, 35043, Marburg, Deutschland.

Der Internist
|March 23, 2016
PubMed
Summary
This summary is machine-generated.

Myasthenia gravis is an autoimmune disorder causing muscle weakness due to antibodies attacking acetylcholine receptors. Treatment includes medications and addressing thymus issues, with crises requiring intensive care.

Keywords:
AcetylcholineAcetylcholine esterase inhibitorsAutoimmune diseasesNeuromuscular diseasesThymus gland

More Related Videos

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.9K
Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models
04:30

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models

Published on: March 8, 2024

1.8K

Related Experiment Videos

Last Updated: Mar 23, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.9K
Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.9K
Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models
04:30

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models

Published on: March 8, 2024

1.8K

Area of Science:

  • Neurology
  • Immunology
  • Autoimmune Diseases

Background:

  • Myasthenia gravis (MG) is an autoimmune condition affecting neuromuscular junctions.
  • It results in antibodies targeting nicotinic acetylcholine receptors (AChR), impairing signal transmission.
  • Thymus disorders are implicated in the pathogenesis of AChR antibody-positive MG.

Purpose of the Study:

  • To provide a comprehensive overview of myasthenia gravis.
  • To detail the autoimmune mechanisms and clinical manifestations.
  • To outline current treatment strategies and management of myasthenic crisis.

Main Methods:

  • Review of existing literature on myasthenia gravis.
  • Analysis of the pathophysiology involving AChR antibodies and the thymus.
  • Description of clinical symptoms, diagnostic considerations, and therapeutic interventions.

Main Results:

  • Myasthenia gravis is characterized by autoantibodies against postsynaptic nicotinic acetylcholine receptors.
  • Clinical presentation varies from ocular to generalized muscle weakness.
  • Effective treatments include acetylcholinesterase inhibitors and immunosuppressants.

Conclusions:

  • Myasthenia gravis requires a multi-faceted treatment approach.
  • Understanding the autoimmune basis is crucial for managing the disease.
  • Prompt recognition and intensive care are vital for myasthenic crises.